Finally, we confirmed that B7-H3 is an emerging negative prognostic marker in AML and established an SFI cut-off value of 4.5, which, together with established prognostic values, allows its application for AML risk stratification. This evidence concerns the gene CD276 and acute myeloid leukemia.